How many FDA actions has Glaxosmithkline Consumer Healthcare Holdings DBA Haleon had?

Argus HQ has recorded 3 FDA events for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon: 0 warning letters, 3 recalls, 0 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

What is the most recent FDA action against Glaxosmithkline Consumer Healthcare Holdings DBA Haleon?

The most recent FDA event Argus HQ has on file for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon is dated 2023-02-01, with a severity rating of "critical" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Does Argus HQ track new FDA actions for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Glaxosmithkline Consumer Healthcare Holdings DBA Haleon is observed, this page's event count and history update automatically.

How many FDA actions does Argus HQ track for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon?

3 total: 0 warning letters, 3 recalls, 0 approval records, and 0 Form 483 inspection citations.

FDA Actions Against Glaxosmithkline Consumer Healthcare Holdings DBA Haleon

Here's the summary: Argus HQ has recorded 3 FDA events for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon: 0 warning letters, 3 recalls, 0 approvals, and 0 inspection 483 observations. These events span from 2023-02-01 to 2023-02-01. The most severe rating Argus HQ has assigned across this history is "critical". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

FDA action counts

Total FDA actions	3
Warning letters	0
Recalls	3
Approval records	0
Form 483 inspection citations	0
Most recent action	February 1, 2023

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Glaxosmithkline Consumer Healthcare Holdings DBA Haleon has 3 separate FDA recalls on file, more than a single isolated recall event. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Enforcement history

On 2023-02-01, Argus HQ recorded an FDA recall for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon, rated "critical" severity in Argus HQ's classification: Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Class I recall: Advil (ibuprofen) Tablets, 200 mg, packaged as a) 360-count bottles (UPC 3 0573…. On 2023-02-01, Argus HQ recorded an FDA recall for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon, rated "critical" severity in Argus HQ's classification: Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Class I recall: Advil Liqui Gels (minis), Solubilized ibuprofen capsules, 200mg, Pain Reliever F…. On 2023-02-01, Argus HQ recorded an FDA recall for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon, rated "critical" severity in Argus HQ's classification: Glaxosmithkline Consumer Healthcare Holdings DBA Haleon — Class I recall: Advil Liqui Gels, Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Red…. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Frequently asked questions

How many FDA actions has Glaxosmithkline Consumer Healthcare Holdings DBA Haleon had?: Argus HQ has recorded 3 FDA events for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon: 0 warning letters, 3 recalls, 0 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
What is the most recent FDA action against Glaxosmithkline Consumer Healthcare Holdings DBA Haleon?: The most recent FDA event Argus HQ has on file for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon is dated 2023-02-01, with a severity rating of "critical" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Does Argus HQ track new FDA actions for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon automatically?: Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Glaxosmithkline Consumer Healthcare Holdings DBA Haleon is observed, this page's event count and history update automatically.
How many FDA actions does Argus HQ track for Glaxosmithkline Consumer Healthcare Holdings DBA Haleon?: 3 total: 0 warning letters, 3 recalls, 0 approval records, and 0 Form 483 inspection citations.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Verified from FDA.gov · Last updated: Feb 1, 2023

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2023). FDA Actions Against Glaxosmithkline Consumer Healthcare Holdings DBA Haleon. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/company/glaxosmithkline-consumer-healthcare-holdings-dba-haleon

MLA

"FDA Actions Against Glaxosmithkline Consumer Healthcare Holdings DBA Haleon." Argus HQ Research, Digital Empire Holdings LLC, 2023, argushq.ai/company/glaxosmithkline-consumer-healthcare-holdings-dba-haleon.

Chicago

Argus HQ Research. "FDA Actions Against Glaxosmithkline Consumer Healthcare Holdings DBA Haleon." Digital Empire Holdings LLC. Accessed July 17, 2026. https://argushq.ai/company/glaxosmithkline-consumer-healthcare-holdings-dba-haleon.

BibTeX

@misc{argushq_argushq_ai_company_glaxosmithkline_consumer_healthcare_holdings_dba_haleon_2023,
  title = {FDA Actions Against Glaxosmithkline Consumer Healthcare Holdings DBA Haleon},
  author = {{Argus HQ Research}},
  year = {2023},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/company/glaxosmithkline-consumer-healthcare-holdings-dba-haleon},
  note = {Accessed: July 17, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗